ALK-Abelló A/S (CPSE: ALK B)
Health Care · Pharmaceuticals · DK
Dkr248.40
-0.16% today · +7.9% 1Y
Public summary
A free snapshot of ALK-Abelló A/S, with figures as of Nov 15, 2026. The full analysis is in the app.Open in the app ALK-Abelló A/S (CPSE: ALK B) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $8.14B.
Over the last twelve months the share price has gained 7.9%, trading between 191.80 and 271.40.
Tweenvest scores ALK-Abelló A/S across four factors: quality 81/100, value 51/100, growth 88/100, dividend 17/100. Its strongest factor is growth.
ALK B price history
Key figures
- Market cap
- $8.14B
- Revenue (TTM)
- $1.04B
- P/E
- 40.73
- EPS
- 6.10
- Dividend yield
- 0.64%
- Beta (5Y)
- 0.74
- 52-week high
- Dkr271.40
- 52-week low
- Dkr191.80
- Avg volume (3M)
- —
- Shares outstanding
- 221.88M
- Employees
- —
- Next earnings
- —
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eisai Co., Ltd.TSE: 4523 | $9.29B | ¥5,240.00 | -1.06% |
| H. Lundbeck A/SCPSE: HLUN B | $8.99B | Dkr62.15 | +2.22% |
| Kyowa Kirin Co., Ltd.TSE: 4151 | $8.39B | ¥2,552.50 | -1.05% |
| Krka, d. d.LJSE: KRKG | $8.29B | €250.00 | -0.40% |
| Glenmark Pharmaceuticals LimitedNSEI: GLENMARK | $7.88B | Rs2,608.50 | -1.42% |
| Asymchem Laboratories (Tianjin) Co., Ltd.SZSE: 002821 | $7.75B | CN¥147.41 | -3.45% |
| Shanghai Fosun Pharmaceutical (Group) Co., Ltd.SHSE: 600196 | $7.62B | CN¥20.71 | -0.53% |
| Corcept Therapeutics IncorporatedNasdaqCM: CORT | $7.42B | $67.79 | -3.25% |